Peijia Medical Ltd. (9996) AI Stock Analysis

• Market Cap: €3.87B
• Dividend Yield: N/A
• Average Volume (3M): 1.88M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: 29.25%
• EPS Growth: 9.02%
• Country: HK
• Employees: 1,047
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.11
• Shares Outstanding: 671,438,200
• 10 Day Avg. Volume: 1,295,000
• 30 Day Avg. Volume: 1,883,282
• PEG Ratio: 0.27
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 4.07
• P/FCF Ratio: -8.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: HK$5.00 ▼(-5.84% Downside)

Peijia Medical Ltd.'s overall stock score is primarily impacted by its financial performance, characterized by strong revenue growth but significant profitability and cash flow challenges. The technical analysis indicates bearish momentum, while the valuation is constrained by ongoing losses and lack of dividends.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing market demand and successful product adoption, which can enhance long-term business sustainability.

Equity Position

A strong equity base provides financial stability and resilience, supporting future growth and investment opportunities.

Market Expansion

Strategic partnerships enhance market reach and product distribution, supporting long-term revenue growth and competitive positioning.

Negative Factors

Profitability Challenges

Ongoing profitability challenges can hinder reinvestment and growth, affecting the company's ability to achieve sustainable financial health.

Cash Flow Issues

Lack of free cash flow limits financial flexibility and increases reliance on external financing, posing risks to long-term operations.

Debt Levels

Rising debt levels without profitability can strain financial resources and increase vulnerability to economic fluctuations.

Peijia Medical Ltd. Business Overview & Revenue Model

Company Description

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.

How the Company Makes Money

Peijia Medical generates revenue primarily through the sale of its interventional medical devices to hospitals and healthcare providers. The company has established a robust distribution network, allowing it to reach a wide customer base both domestically and internationally. Key revenue streams include sales from its flagship products such as stents and catheters, which are critical for various procedures in cardiovascular and neurovascular health. Additionally, Peijia Medical may engage in partnerships with healthcare institutions and research organizations to develop new technologies, which can also contribute to its earnings through collaborative projects and shared innovations. The company benefits from increasing healthcare spending in China and a growing demand for advanced medical solutions, which are significant factors driving its revenue growth.

Peijia Medical Ltd. Financial Statement Overview

Summary

Peijia Medical Ltd. demonstrates strong revenue growth but faces persistent losses and cash flow challenges. The strong equity base provides some financial stability, yet achieving sustainable profitability is crucial.

Income Statement

Peijia Medical Ltd. shows significant revenue growth from 2023 to 2024, with a 39.5% increase. However, the company continues to experience negative EBIT and net income, resulting in negative profit margins. This indicates ongoing challenges in attaining profitability despite growing sales.

Balance Sheet

The company maintains a strong equity position, with a high equity ratio of 75.4% in 2024, reflecting financial stability. However, the debt-to-equity ratio has increased slightly, and the company is still not profitable, which could pose risks if financial conditions change.

Cash Flow

Peijia Medical Ltd. continues to face challenges in cash flow, with zero free cash flow in 2024. The absence of operating cash flow growth and reliance on external financing over the years highlight liquidity risks despite a reduction in net debt.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	667.66M	615.48M	441.13M	250.83M	136.53M	38.66M
Gross Profit	462.38M	433.62M	325.37M	176.20M	95.65M	25.22M
EBITDA	-167.28M	-176.59M	-348.52M	-359.90M	-546.54M	-190.87M
Net Income	-225.18M	-226.58M	-392.52M	-407.81M	-574.22M	-2.07B
Balance Sheet
Total Assets	2.60B	2.69B	2.67B	3.32B	3.16B	2.88B
Cash, Cash Equivalents and Short-Term Investments	608.50M	712.52M	942.92M	1.74B	2.30B	2.46B
Total Debt	322.28M	253.40M	221.13M	131.88M	7.63M	9.13M
Total Liabilities	614.64M	644.11M	397.88M	678.86M	144.48M	67.99M
Stockholders Equity	1.97B	2.03B	2.27B	2.64B	3.02B	2.81B
Cash Flow
Free Cash Flow	-153.20M	-285.29M	-899.67M	-506.61M	-506.11M	-206.35M
Operating Cash Flow	36.21M	-5.18M	-583.49M	-376.20M	-436.37M	-181.10M
Investing Cash Flow	-84.06M	-140.38M	-386.29M	-463.28M	-424.75M	-12.48M
Financing Cash Flow	12.05M	10.38M	85.11M	117.44M	741.98M	2.34B

Peijia Medical Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9996, the sentiment is Negative. The current price of 5.31 is below the 20-day moving average (MA) of 5.71, below the 50-day MA of 6.11, and below the 200-day MA of 6.15, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 36.05 is Neutral, neither overbought nor oversold. The STOCH value of 16.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9996.

Peijia Medical Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2190	58 Neutral	HK$8.47B	47.98	4.99%	0.44%	35.01%	483.73%
2172	58 Neutral	HK$6.15B	27.82	11.79%	1.55%	-5.18%	-9.69%
1858	55 Neutral	HK$10.67B	26.67	8.69%	1.74%	14.56%	61.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	43 Neutral	HK$2.70B	509.09	0.22%	―	-4.38%	―
0853	40 Underperform	$21.88B	-16.56	-24.77%	―	-1.04%	60.66%
9996	39 Underperform	€3.87B	-15.77	-11.20%	―	29.25%	9.02%

Peijia Medical Ltd. Corporate Events

Peijia Medical’s GeminiOne® System Gains NMPA Registration Acceptance

Peijia Medical Ltd. announced that its registration application for the GeminiOne® transcatheter edge-to-edge repair system has been accepted by the National Medical Products Administration of China. This novel device, featuring a unique sliding groove mechanism and other innovations, aims to simplify procedures and accommodate a wider range of anatomical variations, potentially enhancing the company’s market position in the medical device industry.

The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Initiates Clinical Trial for Robotic-Assisted TAVR System

Peijia Medical Ltd. announced the successful enrollment of the first patient in a multi-center registration clinical trial for its ReachTactile™ robotic-assisted TAVR system. This trial aims to evaluate the safety and efficacy of the system, which features a mobile, modular design and real-time tactile feedback for precise navigation in complex vascular conditions. The outcome of this trial will support the company’s future registration application with the National Medical Products Administration, potentially enhancing its market position in the medical technology industry.

The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical’s Strategic Investment Yields Breakthrough in Cardiac Treatment

Peijia Medical Limited announced the successful first implantation in the first-in-man clinical trial of the Sutra Hemi-valve Transcatheter Mitral Valve Repair System, a key product of Sutra Medical, Inc. The procedure, performed on a high-risk patient with severe mitral regurgitation at Waikato Hospital in New Zealand, marks a significant milestone in the development of innovative cardiac treatments. This advancement highlights Peijia Medical’s strategic investment in cutting-edge medical technologies, potentially enhancing its market position and offering new solutions for patients with limited treatment options.

The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Ltd. Reports Strong Revenue Growth and Operational Improvements in H1 2025

Peijia Medical Ltd. reported a 17.3% increase in revenue for the first half of 2025, driven by robust sales growth in its TAVR and neurointerventional businesses. The company achieved significant market share gains in China’s transfemoral TAVR market and launched new premium products, contributing to a 24.0% rise in TAVR-related sales. Neurointerventional product sales also grew by 12.2%, supported by market penetration of existing products and the introduction of the YonFlow Flow Diverting Stent. Operational efficiency improvements led to a 42.4% increase in the Neurointerventional Business segment profit and a narrowing of losses in the Transcatheter Valve Therapeutic Business. Overall, Peijia Medical’s strategic initiatives and market education efforts have strengthened its position as a leading TAVR brand in China.

The most recent analyst rating on (HK:9996) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Ltd. Schedules Board Meeting for Interim Results Review

Peijia Medical Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for the payment of an interim dividend, highlighting the company’s ongoing financial activities and potential shareholder returns.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Reports Strong Growth in H1 2025

Peijia Medical Ltd. announced unaudited operating statistics for the first half of 2025, highlighting a revenue increase driven by market share gains in the TAVR sector and the introduction of premium products. The company expanded its TAVR portfolio into over 70 new hospitals, achieving significant growth in implantations. The launch of new neurointerventional products also contributed to robust performance, indicating strong market positioning and potential future growth.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.